The spectrum of factor VII deficiencies and abnormalities.

(a) The statement that ‘‘The treatment of choice for severe factor VII deficiency is probably rFVIIa [recombinant activated factor VII] etc.’’ is wrong and not supported by the manufacturer. There is no published study showing a superiority of this concentrate with respect to other concentrates from which such a statement can be derived. The rare but definite prothrombotic complications shown with the use of this concentrate even in hemophilia A patients cannot be disregarded.

[1]  T. Ortel,et al.  Management of lepirudin therapy for a patient with antiphospholipid antibody syndrome using the whole blood ecarin clot time and activated partial thromboplastin time , 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[2]  Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  H. Roberts.  Recombinant factor VIIa (Novoseven) and the safety of treatment. , 2001, Seminars in hematology.

[4]  E. Tuddenham,et al.  Inherited Factor VII Deficiency: Genetics and Molecular Pathology , 1995, Thrombosis and Haemostasis.

[5]  A. Kumar,et al.  The dysfunction of coagulation factor VIIPadua results from substitution of arginine-304 by glutamine. , 1993, Biochimica et biophysica acta.

[6]  G. Patrassi,et al.  Faktor-VII-Mangel und Varianten , 1984 .

[7]  F. Fabris,et al.  A COMMENT ON THE CLASSIFICATION OF FACTOR VII VARIANTS , 1982 .

[8]  A. Girolami,et al.  Further studies on factor VII padua defect: the report of the fourth homozygous patient from the same valley , 1982, Blut: Zeitschrift für die Gesamte Blutforschung.

[9]  A. Girolami,et al.  Factor VII Padua 2: another factor VII abnormality with defective ox brain thromboplastin activation and a complex hereditary pattern. , 1979, Blood.

[10]  A. Girolami,et al.  Another Family with the Factor VII Padua Clotting Defect , 1979 .

[11]  F. Fabris,et al.  Factor VII Padua: a congenital coagulation disorder due to an abnormal factor VII with a peculiar activation pattern. , 1978, The Journal of laboratory and clinical medicine.

[12]  G. Falezza,et al.  Factor VII verona coagulation disorder: double heterozygosis with an abnormal factor VII and heterozygous factor VII deficiency. , 1977, Blood.

[13]  Claire Wilson,et al.  Congenital SPCA deficiency: a hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fractions. , 1951, The Journal of clinical investigation.

[14]  A. Leaf,et al.  The effects of adrenocorticotropic hormone and cortisone in the adrenogenital syndrome associated with congenital adrenal hyperplasia: an attempt to explain and correct its disordered hormonal pattern. , 1951, The Journal of clinical investigation.

[15]  D. Cooper,et al.  Inherited Factor X Deficiency: Molecular Genetics and Pathophysiology , 1997, Thrombosis and Haemostasis.

[16]  A. Girolami,et al.  Report of the fifth homozygous patient with factor VII Padua defect. , 1983, Folia haematologica.

[17]  A. Girolami,et al.  Factor VII Padua defect: the heterozygote population. , 1982, Acta haematologica.

[18]  A. Girolami.  The congenital factor VII abnormalities (dysproconvertinemias). The genetic plot thickens. , 1980, Folia haematologica.

[19]  A. Girolami,et al.  Factor VII survival studies in factor VII Padua abnormality. , 1980, Acta haematologica.

[20]  A. Girolami.  The congenital variants of the prothrombin complex factors. , 1980, Acta haematologica.